Andrew Krakauer - Teleflex Incorporated Independent Director
| TFX Stock | USD 167.43 0.18 0.11% |
Director
Mr. Andrew Krakauer is Independent Director of the company. Mr. Krakauer was a director of Teleflex since 2018 and currently serves as a member of the Compensation Committee. Prior to his retirement in October 2016, Mr. Krakauer was Chief Executive Officer of Cantel Medical Corporationration, a provider of infection control products and services. During his 12 years at Cantel, Mr. Krakauer served in various executive and senior level positions, including Chief Executive Officer from November 2014 to July 2016 President and Chief Executive Officer from March 2009 to November 2014 President from April 2008 to March 2009 and Executive Vice President and Chief Operating Officer from August 2004 through April 2008. Mr. Krakauer also served as a member of Cantels board of directors from 2009 to 2016. Prior to joining Cantel, Mr. Krakauer was President of the Ohmeda Medical Division of Instrumentarium Corporationration, a provider of medical devices, from 1998 to 2004. Mr. Krakauers executive and senior management experience in the medical device industry enables him to provide valuable insights regarding a wide range of business matters, including strategy, acquisitions, management, operations and growth initiatives. since 2018.
| Age | 66 |
| Tenure | 7 years |
| Address | 550 East Swedesford Road, Wayne, PA, United States, 19087-1603 |
| Phone | 610-225-6800 |
| Web | https://www.teleflex.com |
Teleflex Incorporated Management Efficiency
The company has Return on Asset of 0.0315 % which means that on every $100 spent on assets, it made $0.0315 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0541 %, implying that it generated $0.0541 on every 100 dollars invested. Teleflex Incorporated's management efficiency ratios could be used to measure how well Teleflex Incorporated manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Teleflex Incorporated's Return On Capital Employed is fairly stable compared to the past year. Return On Assets is likely to rise to 0.06 in 2025, whereas Return On Tangible Assets are likely to drop 0.08 in 2025. At this time, Teleflex Incorporated's Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 7.4 B in 2025, whereas Total Current Assets are likely to drop slightly above 892.1 M in 2025.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Maria Rivas | The Cooper Companies, | 57 | |
| Myla LaiGoldman | West Pharmaceutical Services | 62 | |
| Jesse Wu | AptarGroup | 62 | |
| Catherine Burzik | Haemonetics | 70 | |
| Colleen Jay | The Cooper Companies, | 58 | |
| Paolo Pucci | West Pharmaceutical Services | 59 | |
| Timothy Ring | Becton Dickinson and | 63 | |
| Rebecca Rimel | Becton Dickinson and | 69 | |
| Kim Duncan | The Cooper Companies, | N/A | |
| Jody Lindell | The Cooper Companies, | 69 | |
| Bertram Scott | Becton Dickinson and | 69 | |
| Maritza Montiel | AptarGroup | 69 | |
| Carol Burt | ResMed Inc | 62 | |
| Claire Fraser | Becton Dickinson and | 65 | |
| Richard Sulpizio | ResMed Inc | 70 | |
| Arthur MD | Alcon AG | 63 | |
| Joanne Smith | AptarGroup | 59 | |
| David Melcher | Becton Dickinson and | 66 | |
| Claire Pomeroy | Haemonetics | 65 | |
| Andreas Kramvis | AptarGroup | 68 | |
| Deborah Tanner | West Pharmaceutical Services | 57 | |
Management Performance
| Return On Equity | 0.0541 | ||||
| Return On Asset | 0.0315 |
Teleflex Incorporated Leadership Team
Elected by the shareholders, the Teleflex Incorporated's board of directors comprises two types of representatives: Teleflex Incorporated inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Teleflex. The board's role is to monitor Teleflex Incorporated's management team and ensure that shareholders' interests are well served. Teleflex Incorporated's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Teleflex Incorporated's outside directors are responsible for providing unbiased perspectives on the board's policies.
| MBA BS, Executive CFO | ||
| Michelle Fox, Corporate Officer | ||
| Roger Graham, President Interventional | ||
| Timothy Duffy, VP Officer | ||
| John Heinmiller, Independent Director | ||
| John CFA, VP Relations | ||
| Andrew Krakauer, Independent Director | ||
| Howard Cyr, Corporate Officer | ||
| Liam Kelly, Chairman of the Board, President, Chief Executive Officer | ||
| Matthew James, EMEA President | ||
| Lawrence Keusch, Vice Development | ||
| Stephen Klasko, Independent Director | ||
| George Babich, Lead Independent Director | ||
| Matt Tomkin, VP Devel | ||
| Jake Newman, President Americas | ||
| Daniel JD, General VP | ||
| James Leyden, Corporate Vice President, General Counsel, Secretary | ||
| Thomas Powell, Chief Financial Officer, Executive Vice President | ||
| Cameron Hicks, Corporate Vice President - Human Resources and Communications | ||
| Mario Wijker, Corporate Vice President - Quality Assurance and Regulatory Affairs | ||
| Jay White, Corporate Vice President and President Global Commercial | ||
| Karen Boylan, Vice President - Global Strategic Projects | ||
| James Winters, Corporate Vice President - Manufacturing and Supply Chain | ||
| James Ferguson, President Surgical | ||
| John Deren, Chief Accounting Officer, Vice President | ||
| Candace Duncan, Independent Director | ||
| Richard Packer, Independent Director | ||
| Praneet Mehrotra, President APAC | ||
| Stuart Randle, Independent Director | ||
| Lisa Kudlacz, President Vascular | ||
| Gretchen Haggerty, Independent Director | ||
| Daniel Logue, Corporate Vice President General Counsel and Secretary |
Teleflex Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Teleflex Incorporated a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0541 | ||||
| Return On Asset | 0.0315 | ||||
| Profit Margin | 0.08 % | ||||
| Operating Margin | 0.20 % | ||||
| Current Valuation | 9.39 B | ||||
| Shares Outstanding | 46.44 M | ||||
| Shares Owned By Insiders | 0.41 % | ||||
| Shares Owned By Institutions | 99.59 % | ||||
| Number Of Shares Shorted | 1.15 M | ||||
| Price To Earning | 38.28 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Teleflex Stock Analysis
When running Teleflex Incorporated's price analysis, check to measure Teleflex Incorporated's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Teleflex Incorporated is operating at the current time. Most of Teleflex Incorporated's value examination focuses on studying past and present price action to predict the probability of Teleflex Incorporated's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Teleflex Incorporated's price. Additionally, you may evaluate how the addition of Teleflex Incorporated to your portfolios can decrease your overall portfolio volatility.